One of these (NCT03473925, estimated completion date May 15, 2021) is a phase II clinical trial in which navarixin in combination with the PD-1 antagonist, pembrolizumab, is being investigated in adults (n = 120) with PD-L1-positive, refractory NSCLC, as well as in castration-resistant prostate cancer and microsatellite stable colorectal cancer (NIH, 2021a). Here, CD274 is linked to non-small cell lung carcinoma.